Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: African trypanosomiasis therapies - Pfizer/DNDi/SCYNEXIS

Drug Profile

Research programme: African trypanosomiasis therapies - Pfizer/DNDi/SCYNEXIS

Alternative Names: AN-2920; AN-3520; AN-4169; SCYX-1330682; SCYX-1608210; SCYX-6759

Latest Information Update: 23 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Anacor Pharmaceuticals; Drugs for Neglected Diseases Initiative Foundation; SCYNEXIS
  • Developer Drugs for Neglected Diseases Initiative Foundation; Pfizer; SCYNEXIS
  • Class Benzamides; Organic boron compounds; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research African trypanosomiasis

Most Recent Events

  • 23 Nov 2018 Early research for African trypanosomiasis therapies is ongoing in USA (DNDi pipeline, November 2018)
  • 04 Nov 2017 No recent reports of development identified for early research in African trypanosomiasis in USA (PO)
  • 24 Jun 2016 Anacor Pharmaceuticals has been acquired by Pfizer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top